Annual report
3583.TEDINET S100YK22
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥6.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥5.4bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.3bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥615m | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥841m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥630m | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥814m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥601m | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥639m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥727m | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥636m | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥819m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥573m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥580m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥436m | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥469m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥537m | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥573m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥580m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥10.2bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥9.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥9.7bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥9.3bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥9.4bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.9bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥3.1bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.3bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.3bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥5.4bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.5bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.4bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥329m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥637m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥338m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥444m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥160m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥165m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥184m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥189m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥149m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥562m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥451m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥206m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥266m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥209.05 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.05 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.8 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥169.17 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥194.04 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,648.18 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,439.07 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,246.2 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,100.85 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,957.25 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 71.3% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.4% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.5% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.3% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 353 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 368 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 343 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 340 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 364 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥5.4bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥5.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥5.0bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.0bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.3bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥294m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥513m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥393m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥524m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥363m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥492m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥619m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥393m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥529m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥384m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥388m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥260m | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥368m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥440m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.7bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥8.7bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥8.7bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥8.5bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥8.7bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥2.9bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.1bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥5.9bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥5.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥5.3bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥5.1bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.8bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥140.1 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥139.8 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥93.53 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥132.59 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥159.25 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥35 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥33 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,139.5 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,036.45 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,915.08 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,843.5 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,736.4 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 67.0% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.4% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.6% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.5% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.5% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.7% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 3,092,623 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 124 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 125 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 129 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 130 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 132 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥8m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥4m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥313m |
| Medical Productsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥285m |
| Medical Productsreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥70m |
| Medical Productsreportable segment | employees | at 2026-03-31 | 52 pure |
| Medical Productsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥1.8bn |
| Medical Productsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥1.8bn |
| Medical Productsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥4m |
| Medical Productsreportable segment | segment assets | at 2026-03-31 | ¥1.9bn |
| Medical Productsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥162m |
| Technological Productsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥202m |
| Technological Productsreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥216m |
| Technological Productsreportable segment | employees | at 2026-03-31 | 291 pure |
| Technological Productsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥4.2bn |
| Technological Productsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥4.2bn |
| Technological Productsreportable segment | segment assets | at 2026-03-31 | ¥6.0bn |
| Technological Productsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥767m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥487m |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥286m |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥6.0bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥6.0bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥4m |
| —segment total | segment assets | at 2026-03-31 | ¥7.9bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥928m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥1m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥10m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥1m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥343m |
| Medical Productsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥48m |
| Medical Productsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥66m |
| Medical Productsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Medical Productsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Medical Productsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1m |
| Medical Productsreportable segment | segment assets | at 2025-03-31 | ¥1.5bn |
| Medical Productsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥124m |
| Technological Productsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥123m |
| Technological Productsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥213m |
| Technological Productsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥4.3bn |
| Technological Productsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.3bn |
| Technological Productsreportable segment | segment assets | at 2025-03-31 | ¥5.9bn |
| Technological Productsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥171m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥279m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥6.0bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥6.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1m |
| —segment total | segment assets | at 2025-03-31 | ¥7.4bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Medical Productsreportable segment | employees | at 2026-03-31 | 18 pure |
| Technological Productsreportable segment | employees | at 2026-03-31 | 96 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,531
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 125 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 124 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 65 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 70 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 59 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 66 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 77 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.422 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.623 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.575 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 2.272 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 2.213 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.020 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.079 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.525 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.502 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.022 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 10 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 7.7 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 50 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 33.3 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 10 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 2.4 | |
| Research and development expenses research and development activities | CurrentYearDuration | 120000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 76000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 44000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 472000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 187000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 284000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 3092623 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 3092623 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 3092623 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 3092623 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 3 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 15 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 23 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 10 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 1 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 853 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 905 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 2950 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 457 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 15145 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 139 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 1 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 12049 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 30741 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |